Display options
Cite
Kasikis S, Baez J, Gandhi I, et al. Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers. Bone Marrow Transplant. 2021;56(11):2869-2870doi: 10.1038/s41409-021-01442-3.
Kasikis, S., Baez, J., Gandhi, I., Grupp, S., Kitko, C. L., Kowalyk, S., Merli, P., Morales, G., Pulsipher, M. A., Qayed, M., Wölfl, M., Yanik, G., See, F., Hayes, J., Grossman, F., Burke, E., Young, R., Levine, J. E., & Ferrara, J. L. M. (2021). Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers. Bone marrow transplantation, 56(11), 2869-2870. https://doi.org/10.1038/s41409-021-01442-3
Kasikis, Stelios, et al. "Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers." Bone marrow transplantation vol. 56,11 (2021): 2869-2870. doi: https://doi.org/10.1038/s41409-021-01442-3
Kasikis S, Baez J, Gandhi I, Grupp S, Kitko CL, Kowalyk S, Merli P, Morales G, Pulsipher MA, Qayed M, Wölfl M, Yanik G, See F, Hayes J, Grossman F, Burke E, Young R, Levine JE, Ferrara JLM. Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers. Bone Marrow Transplant. 2021 Nov;56(11):2869-2870. doi: 10.1038/s41409-021-01442-3. Epub 2021 Sep 01. PMID: 34471240.
Copy Download .nbib Format: NLM
Share it on

Bone Marrow Transplant. 2021 Nov;56(11):2869-2870. doi: 10.1038/s41409-021-01442-3. Epub 2021 Sep 01.

Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers.

Bone marrow transplantation

Stelios Kasikis, Janna Baez, Isha Gandhi, Stephan Grupp, Carrie L Kitko, Steven Kowalyk, Pietro Merli, George Morales, Michael A Pulsipher, Muna Qayed, Matthias Wölfl, Gregory Yanik, Fiona See, Jack Hayes, Fred Grossman, Elizabeth Burke, Rachel Young, John E Levine, James L M Ferrara

Affiliations

  1. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  2. Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  3. Vanderbilt University Medical Center, Nashville, TN, USA.
  4. Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale Pediatrico Bambino Gesù, Rome, Italy.
  5. Section of Transplantation and Cellular Therapy, Children's Hospital Los Angeles, Los Angeles, CA, USA.
  6. Aflac Cancer and Blood Disorders Center, Emory University and Children's Healthcare of Atlanta, Atlanta, GA, USA.
  7. Children's Hospital, University of Würzburg, Würzburg, Germany.
  8. University of Michigan, Ann Arbor, MI, USA.
  9. Mesoblast, Inc., New York, NY, USA.
  10. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. [email protected].

PMID: 34471240 DOI: 10.1038/s41409-021-01442-3

[No abstract available.]

References

  1. Kurtzberg J, Abdel-Azim H, Carpenter P, Chaudhury S, Horn B, Mahadeo K, et al. A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease. Biol Blood Marrow Transpl. 2020;26:845–54. - PubMed
  2. Cahn JY, Klein JP, Lee SJ, Milpied N, Blaise D, Antin JH, et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood. 2005;106:1495–500. - PubMed
  3. Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, et al. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI Insight. 2017;2:e89798. - PubMed
  4. Ferrara JLM, Chaudhry MS. GVHD: biology matters. Blood Adv. 2018;2:3411–7. - PubMed
  5. Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, et al. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood. 2018;131:2846–55. - PubMed
  6. Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, et al. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood. 2018;131:2846–55. https://doi.org/10.1182/blood-2018-01-822957 . - PubMed
  7. Srinagesh HK, Özbek U, Kapoor U, Ayuk F, Aziz M, Ben-David K, et al. The MAGIC Algorithm Probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv. 2019;3:4034–42. - PubMed
  8. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105:1815–22. - PubMed
  9. Auletta JJ, Eid SK, Wuttisarnwattana P, Silva I, Metheny L, Keller MD, et al. Human mesenchymal stromal cells attenuate graft-versus-host disease and maintain graft-versus-leukemia activity following experimental allogeneic bone marrow transplantation. Stem Cells. 2015;33:601–14. - PubMed

Publication Types

Grant support